Melanie M. Tidman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melanie M. Tidman has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dawn Reid White
National University
9 shared publications - Tim A. White
American Public University System
8 shared publications Adrian Swart
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
1 shared publicationErin Skotzke
Department of Occupational Therapy, Nova Southeastern University, Fort Lauderdale, FL, USA
1 shared publication- Henry M. Walker
Kaiser Foundation Hospital
1 shared publication - Jeffrey R. Pua
Department of Obesity Medicine, Duly Healthcare, Westmont, Illinois, United States
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 12
Effects of three nutritional approaches on metabolic health and Parkinson’s disease: A 32-week crossover study
Background: Parkinson’s disease (PD) is a neurodegenerative disorder with motor and non-motor symptoms that impair quality of life. Altered neuronal glucose metabolism may contribute to PD symptoms, suggesting a potential role for nutritional interventions. Aim: To examine three dietary approaches in relation to PD symptoms, sleep, fatigue, cognition, and metabolic biomarkers. Setting: This 32-week, fully virtual crossover study recruited participants across the United States. Interventions, assessments, and monitoring were completed remotely. Methods: Sixteen participants completed three 8-week dietary phases separated by 4-week washouts. Glucose and ketones were monitored during Phases II and III. Laboratory measures were obtained at baseline and after each phase. Standardised PD scales, exit surveys, adherence and interviews assessed outcomes and participant experiences. Results: Body weight and glycated haemoglobin improved significantly during the low-carbohydrate ketogenic diet plus medium-chain triglyceride (MCT) oil phase. Changes in PD-specific scale scores were not statistically significant. Participants qualitatively reported improvements in energy, cognitive clarity, sleep, and selected PD symptoms. Conclusion: A low-carbohydrate ketogenic diet with MCT oil may improve metabolic outcomes and selected patient-perceived symptoms in PD. Adherence and gastrointestinal intolerance may affect long-term feasibility. Contribution: This study provides preliminary evidence on nutritional interventions, metabolic health, and PD-related symptoms. It also demonstrates the feasibility of remote nutritional research using telehealth, home monitoring, and standardised PD scales. Larger controlled trials are needed to determine whether metabolic improvements translate into clinically meaningful PD outcomes.
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 12
Open AccessEffects of three nutritional approaches on metabolic health and Parkinson’s disease: A 32-week crossover study
Background: Parkinson’s disease (PD) is a neurodegenerative disorder with motor and non-motor symptoms that impair quality of life. Altered neuronal glucose metabolism may contribute to PD symptoms, suggesting a potential role for nutritional interventions. Aim: To examine three dietary approaches in relation to PD symptoms, sleep, fatigue, cognition, and metabolic biomarkers. Setting: This 32-week, fully virtual crossover study recruited participants across the United States. Interventions, assessments, and monitoring were completed remotely. Methods: Sixteen participants completed three 8-week dietary phases separated by 4-week washouts. Glucose and ketones were monitored during Phases II and III. Laboratory measures were obtained at baseline and after each phase. Standardised PD scales, exit surveys, adherence and interviews assessed outcomes and participant experiences. Results: Body weight and glycated haemoglobin improved significantly during the low-carbohydrate ketogenic diet plus medium-chain triglyceride (MCT) oil phase. Changes in PD-specific scale scores were not statistically significant. Participants qualitatively reported improvements in energy, cognitive clarity, sleep, and selected PD symptoms. Conclusion: A low-carbohydrate ketogenic diet with MCT oil may improve metabolic outcomes and selected patient-perceived symptoms in PD. Adherence and gastrointestinal intolerance may affect long-term feasibility. Contribution: This study provides preliminary evidence on nutritional interventions, metabolic health, and PD-related symptoms. It also demonstrates the feasibility of remote nutritional research using telehealth, home monitoring, and standardised PD scales. Larger controlled trials are needed to determine whether metabolic improvements translate into clinically meaningful PD outcomes.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 6
Targeting insulin and leptin in obesity management: A case series in metabolic health practice
A low-carbohydrate ketogenic (LCK) diet implemented in a metabolic health practice was evaluated for its association with changes in fasting hyperinsulinemia, fasting hyperleptinemia and other metabolic biomarkers in adults with obesity. Six adults with obesity were recruited from the Duly Weight Loss Clinic in Westmont, Illinois, between 2022 and 2025. The cohort comprised three men and three women with a body mass index (BMI) > 30 kg/m2 who followed an LCK diet without anti-obesity pharmacotherapy. Participants were monitored for 12 months with visits every 30–60 days that included counselling, coaching and fasting beta-hydroxybutyrate checks. Outcomes measured were changes in body weight, fasting insulin, fasting leptin and haemoglobin A1c (HbA1c). All six participants achieved clinically meaningful weight loss over 12 months. Mean weight reduction was 25% from baseline. Fasting insulin decreased by a mean of 15.3 mIU/L, representing a 64% reduction. Fasting leptin decreased by a mean of 25.5 ng/mL, corresponding to an 80% reduction. Haemoglobin A1c decreased by a mean of 0.27%. Weight reduction was accompanied by reductions in fasting insulin and fasting leptin, while HbA1c remained relatively stable. An LCK dietary approach combined with structured lifestyle support was associated with substantial weight loss and reductions in fasting insulin and circulating leptin, with HbA1c remaining relatively stable over 12 months. These findings support further investigation of an LCK diet within structured outpatient obesity management. An LCK diet within a structured obesity medicine programme was associated with clinically meaningful weight loss and reductions in fasting insulin and leptin concentrations.
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 6
Open AccessTargeting insulin and leptin in obesity management: A case series in metabolic health practice
A low-carbohydrate ketogenic (LCK) diet implemented in a metabolic health practice was evaluated for its association with changes in fasting hyperinsulinemia, fasting hyperleptinemia and other metabolic biomarkers in adults with obesity. Six adults with obesity were recruited from the Duly Weight Loss Clinic in Westmont, Illinois, between 2022 and 2025. The cohort comprised three men and three women with a body mass index (BMI) > 30 kg/m2 who followed an LCK diet without anti-obesity pharmacotherapy. Participants were monitored for 12 months with visits every 30–60 days that included counselling, coaching and fasting beta-hydroxybutyrate checks. Outcomes measured were changes in body weight, fasting insulin, fasting leptin and haemoglobin A1c (HbA1c). All six participants achieved clinically meaningful weight loss over 12 months. Mean weight reduction was 25% from baseline. Fasting insulin decreased by a mean of 15.3 mIU/L, representing a 64% reduction. Fasting leptin decreased by a mean of 25.5 ng/mL, corresponding to an 80% reduction. Haemoglobin A1c decreased by a mean of 0.27%. Weight reduction was accompanied by reductions in fasting insulin and fasting leptin, while HbA1c remained relatively stable. An LCK dietary approach combined with structured lifestyle support was associated with substantial weight loss and reductions in fasting insulin and circulating leptin, with HbA1c remaining relatively stable over 12 months. These findings support further investigation of an LCK diet within structured outpatient obesity management. An LCK diet within a structured obesity medicine programme was associated with clinically meaningful weight loss and reductions in fasting insulin and leptin concentrations.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 10
How the ketogenic diet affects patients with Parkinson’s disease: A descriptive phenomenological study
Background: For individuals living with Parkinson’s disease (PD), the earliest and most disruptive changes are often not tremor or rigidity, but a gradual loss of mental clarity, physical confidence and social ease that reshapes everyday life. Aim: To explore how individuals with PD described changes in mental, physical and social quality of life (QoL) before and after participating in a 12-week low-carbohydrate, healthy-fat ketogenic dietary intervention. Setting: The study setting consisted of participants recruited through the Colorado Parkinson Foundation, a community-based organisation supporting individuals living with Parkinson’s disease and their caregivers. All participants resided in the United States during the study period. Methods: Sixteen adults diagnosed with PD, aged 36–81 years, participated in this descriptive phenomenological study. Participants were recruited with assistance from the Colorado Parkinson Foundation and resided in the United States. Semi-structured interviews were conducted via Zoom before and after the dietary intervention to capture participants’ lived experiences across time. Results: Pre-study interviews yielded three major themes describing participants’ experiences prior to dietary change, while post-study interviews yielded four major themes reflecting experiences following completion of the intervention. Participants described changes related to mental clarity, physical function, social engagement, metabolic health and relational support. Conclusion: Findings highlight how metabolic-based dietary intervention was experienced in everyday life by individuals living with PD. Participants described improvements in mental clarity, physical function and social engagement that corresponded to observed changes in metabolic health, suggesting a meaningful connection between metabolic adaptation and QoL. Contribution: Centring participant perspectives provides important patient-centred insight into how metabolic changes associated with a ketogenic diet (KD) intervention are experienced and integrated into QoL beyond clinical or biomarker outcomes.
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 10
Open AccessHow the ketogenic diet affects patients with Parkinson’s disease: A descriptive phenomenological study
Background: For individuals living with Parkinson’s disease (PD), the earliest and most disruptive changes are often not tremor or rigidity, but a gradual loss of mental clarity, physical confidence and social ease that reshapes everyday life. Aim: To explore how individuals with PD described changes in mental, physical and social quality of life (QoL) before and after participating in a 12-week low-carbohydrate, healthy-fat ketogenic dietary intervention. Setting: The study setting consisted of participants recruited through the Colorado Parkinson Foundation, a community-based organisation supporting individuals living with Parkinson’s disease and their caregivers. All participants resided in the United States during the study period. Methods: Sixteen adults diagnosed with PD, aged 36–81 years, participated in this descriptive phenomenological study. Participants were recruited with assistance from the Colorado Parkinson Foundation and resided in the United States. Semi-structured interviews were conducted via Zoom before and after the dietary intervention to capture participants’ lived experiences across time. Results: Pre-study interviews yielded three major themes describing participants’ experiences prior to dietary change, while post-study interviews yielded four major themes reflecting experiences following completion of the intervention. Participants described changes related to mental clarity, physical function, social engagement, metabolic health and relational support. Conclusion: Findings highlight how metabolic-based dietary intervention was experienced in everyday life by individuals living with PD. Participants described improvements in mental clarity, physical function and social engagement that corresponded to observed changes in metabolic health, suggesting a meaningful connection between metabolic adaptation and QoL. Contribution: Centring participant perspectives provides important patient-centred insight into how metabolic changes associated with a ketogenic diet (KD) intervention are experienced and integrated into QoL beyond clinical or biomarker outcomes.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 7
Clinical remission of Crohn’s disease symptoms following the adoption of therapeutic carbohydrate reduction: A retrospective single case report
Low-carbohydrate dietary approaches are increasingly explored as adjunctive strategies for Crohn’s disease (CD), particularly in patients who experience limitations or adverse effects with standard biologic therapies. Dietary intervention (DI) may offer a non-pharmacological option to support symptom control and remission. Evidence remains limited, particularly at the individual clinical level. This single-patient, retrospective case report describes an adult with established CD who initiated a therapeutic carbohydrate-restricted diet under clinical guidance. The intervention was implemented as part of ongoing disease management and followed longitudinally during routine care. Clinical outcomes were assessed through symptom patterns, medication use, and sustained follow-up over an extended observation period. Following initiation of the carbohydrate-restricted dietary approach, the patient achieved remission of gastrointestinal symptoms and progressively discontinued pharmacologic therapy. Symptom recurrence was temporally associated with lapses in dietary adherence and resolved promptly upon resumption of the intervention. Sustained adherence was related to continued symptom control and medication independence throughout follow-up. This case suggests that therapeutic carbohydrate reduction may support remission and medication discontinuation in select individuals with CD. The findings underscore the need for controlled clinical trials to evaluate the safety, durability and generalisability of DIs in inflammatory bowel disease. Dietary strategies may represent a complementary avenue for individualised disease management.
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 7
Open AccessClinical remission of Crohn’s disease symptoms following the adoption of therapeutic carbohydrate reduction: A retrospective single case report
Low-carbohydrate dietary approaches are increasingly explored as adjunctive strategies for Crohn’s disease (CD), particularly in patients who experience limitations or adverse effects with standard biologic therapies. Dietary intervention (DI) may offer a non-pharmacological option to support symptom control and remission. Evidence remains limited, particularly at the individual clinical level. This single-patient, retrospective case report describes an adult with established CD who initiated a therapeutic carbohydrate-restricted diet under clinical guidance. The intervention was implemented as part of ongoing disease management and followed longitudinally during routine care. Clinical outcomes were assessed through symptom patterns, medication use, and sustained follow-up over an extended observation period. Following initiation of the carbohydrate-restricted dietary approach, the patient achieved remission of gastrointestinal symptoms and progressively discontinued pharmacologic therapy. Symptom recurrence was temporally associated with lapses in dietary adherence and resolved promptly upon resumption of the intervention. Sustained adherence was related to continued symptom control and medication independence throughout follow-up. This case suggests that therapeutic carbohydrate reduction may support remission and medication discontinuation in select individuals with CD. The findings underscore the need for controlled clinical trials to evaluate the safety, durability and generalisability of DIs in inflammatory bowel disease. Dietary strategies may represent a complementary avenue for individualised disease management.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 6
Synergistic management of metabolic syndrome with postmenopausal osteoporosis: A retrospective case report
Metabolic syndrome (MetS) and postmenopausal osteoporosis (POP) commonly coexist, amplifying cardiovascular and fracture risk through shared mechanisms of insulin resistance, inflammation, and impaired energy metabolism. Conventional management often emphasises pharmacotherapy and calcium supplementation, while overlooking the optimisation of metabolic health. Emerging evidence supports nutritional and exercise-based strategies that target both metabolic and skeletal integrity. This study aimed to evaluate the synergistic effects of a low-carbohydrate and ketogenic diet (LCK), resistance training (RT), and bioavailable calcium supplementation on bone mineral density (BMD) and metabolic health in a patient with concurrent POP and MetS. A 65-year-old postmenopausal woman with baseline osteoporosis and MetS provided documentation for a 36-month, three-phase retrospective data analysis. Phase 1 intervention included an LCK (12 months); Phase 2 combined LCK with RT three times per week (12 months); and Phase 3 added daily bioavailable calcium supplementation (12 months). Bone mineral density was assessed via dual-energy X-ray absorptiometry at baseline, 12, 24, and 36 months. Secondary outcomes included metabolic markers, body composition, and inflammatory indices. Progressive increases in BMD T-scores were observed across major skeletal sites. Metabolic outcomes included improved biomarker levels and favourable changes in weight and waist circumference. No adverse effects occurred. Sometimes KD nutrition may not be enough to preserve BMD. The integration of ketogenic nutrition, RT, and calcium supplementation may synergistically enhance BMD while improving metabolic health in individuals with POP and MetS. This multimodal approach represents a promising adjunct to standard management of MetS and osteoporosis and warrants validation through controlled clinical studies.
- 1 January 2026
- Published by AOSIS in Journal of Metabolic Health
- Vol. 9 (1) , 6
Open AccessSynergistic management of metabolic syndrome with postmenopausal osteoporosis: A retrospective case report
Metabolic syndrome (MetS) and postmenopausal osteoporosis (POP) commonly coexist, amplifying cardiovascular and fracture risk through shared mechanisms of insulin resistance, inflammation, and impaired energy metabolism. Conventional management often emphasises pharmacotherapy and calcium supplementation, while overlooking the optimisation of metabolic health. Emerging evidence supports nutritional and exercise-based strategies that target both metabolic and skeletal integrity. This study aimed to evaluate the synergistic effects of a low-carbohydrate and ketogenic diet (LCK), resistance training (RT), and bioavailable calcium supplementation on bone mineral density (BMD) and metabolic health in a patient with concurrent POP and MetS. A 65-year-old postmenopausal woman with baseline osteoporosis and MetS provided documentation for a 36-month, three-phase retrospective data analysis. Phase 1 intervention included an LCK (12 months); Phase 2 combined LCK with RT three times per week (12 months); and Phase 3 added daily bioavailable calcium supplementation (12 months). Bone mineral density was assessed via dual-energy X-ray absorptiometry at baseline, 12, 24, and 36 months. Secondary outcomes included metabolic markers, body composition, and inflammatory indices. Progressive increases in BMD T-scores were observed across major skeletal sites. Metabolic outcomes included improved biomarker levels and favourable changes in weight and waist circumference. No adverse effects occurred. Sometimes KD nutrition may not be enough to preserve BMD. The integration of ketogenic nutrition, RT, and calcium supplementation may synergistically enhance BMD while improving metabolic health in individuals with POP and MetS. This multimodal approach represents a promising adjunct to standard management of MetS and osteoporosis and warrants validation through controlled clinical studies.
- Open Access
- 28 November 2025
- Published by AOSIS in Journal of Metabolic Health
- Vol. 8 (1) , 4
Symposium for metabolic health 2025: Conference report and summary of highlights
The Journal of Metabolic Health is a peer-reviewed, clinically oriented open access journal covering advances in metabolic health and related disorders. The journal focuses on pathophysiology, prevention, management, and advancing therapy for different patient populations with metabolic health issues, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, and other conditions associated with insulin resistance and inflammation. Articles published in the journal will encompass original research with a broad biomedical approach from bench to bedside, including basic research and clinical case studies. In addition, the journal will feature review articles, perspectives, case studies, case reports and editorials to provide comprehensive coverage and critical insights into the field. The content will be of interest to an academic and clinician-based audience, including medical practitioners, clinical educators, dietitians, nutritionists, nurse practitioners, pharmacists, and other healthcare professionals involved in the study and management of metabolic health disorders.
- 28 November 2025
- Published by AOSIS in Journal of Metabolic Health
- Vol. 8 (1) , 4
Open AccessSymposium for metabolic health 2025: Conference report and summary of highlights
The Journal of Metabolic Health is a peer-reviewed, clinically oriented open access journal covering advances in metabolic health and related disorders. The journal focuses on pathophysiology, prevention, management, and advancing therapy for different patient populations with metabolic health issues, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, and other conditions associated with insulin resistance and inflammation. Articles published in the journal will encompass original research with a broad biomedical approach from bench to bedside, including basic research and clinical case studies. In addition, the journal will feature review articles, perspectives, case studies, case reports and editorials to provide comprehensive coverage and critical insights into the field. The content will be of interest to an academic and clinician-based audience, including medical practitioners, clinical educators, dietitians, nutritionists, nurse practitioners, pharmacists, and other healthcare professionals involved in the study and management of metabolic health disorders.
- Open Access
- 13 June 2024
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 14 (3-4) , 97-110
Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study
Aim: Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.Patients & methods: We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).Results: Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.Conclusion: We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.
- 13 June 2024
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 14 (3-4) , 97-110
Open AccessImpact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study
Aim: Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.Patients & methods: We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).Results: Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.Conclusion: We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.
- Open Access
- 21 December 2023
- Published by AOSIS in Journal of Metabolic Health
- Vol. 7 (1) , 4
Symposium for Metabolic Health 2024: Conference report and summary of highlights
The Journal of Metabolic Health is a peer-reviewed, clinically oriented open access journal covering advances in metabolic health and related disorders. The journal focuses on pathophysiology, prevention, management, and advancing therapy for different patient populations with metabolic health issues, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, and other conditions associated with insulin resistance and inflammation. Articles published in the journal will encompass original research with a broad biomedical approach from bench to bedside, including basic research and clinical case studies. In addition, the journal will feature review articles, perspectives, case studies, case reports and editorials to provide comprehensive coverage and critical insights into the field. The content will be of interest to an academic and clinician-based audience, including medical practitioners, clinical educators, dietitians, nutritionists, nurse practitioners, pharmacists, and other healthcare professionals involved in the study and management of metabolic health disorders.
- 21 December 2023
- Published by AOSIS in Journal of Metabolic Health
- Vol. 7 (1) , 4
Open AccessSymposium for Metabolic Health 2024: Conference report and summary of highlights
The Journal of Metabolic Health is a peer-reviewed, clinically oriented open access journal covering advances in metabolic health and related disorders. The journal focuses on pathophysiology, prevention, management, and advancing therapy for different patient populations with metabolic health issues, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, and other conditions associated with insulin resistance and inflammation. Articles published in the journal will encompass original research with a broad biomedical approach from bench to bedside, including basic research and clinical case studies. In addition, the journal will feature review articles, perspectives, case studies, case reports and editorials to provide comprehensive coverage and critical insights into the field. The content will be of interest to an academic and clinician-based audience, including medical practitioners, clinical educators, dietitians, nutritionists, nurse practitioners, pharmacists, and other healthcare professionals involved in the study and management of metabolic health disorders.
- Open Access
- 21 December 2023
- Published by AOSIS in Journal of Metabolic Health
- Vol. 7 (1) , 6
The ketogenic diet and MetSyn in Parkinson’s disease – Symptoms, biomarkers, depression and anxiety: A case study
The use of therapeutic carbohydrate restriction (TCR) in the form of a ketogenic diet (KD) in neurodegenerative disorders such as Parkinson’s disease (PD) is increasing as an alternative treatment for primary and secondary symptoms. There exists a gap in the literature on symptoms of PD in the setting of metabolic syndrome (MetSyn) and possible comorbid impact on symptoms, biomarkers of health, cardiac risk, depression and anxiety. This case report documents a 24-week KD intervention for a 53-year-old man with multiple comorbid diagnoses, PD (Hoehn-Yahr stage IIa) with a history of morbid obesity with increased waist circumference, prediabetes, hyperinsulinaemia and significantly impaired mobility with chronic back pain, anxiety disorder and depression. Baseline cardiac risk ratios (CRR = triglycerides/HDL) were calculated and compared. The KD approach involved a well-formulated, ketogenic diet (fats 70%; protein 25%; carbohydrates 5% according to total daily energy intake for 24 weeks). Baseline, 12-week and 24-week biomarkers and scores on scales were compared. Clinically significant results were found when baseline biomarker results and scales were compared with 12-week results. Positive trends were seen for all variables at 24 weeks. Improvements in health biomarkers, including HbA1C, high sensitivity C-reactive protein (hs-CRP), triglycerides, fasting insulin, weight loss, waist circumference and cardiac risk were observed at 12 and 24 weeks. Some improvements in scores on an anxiety scale were seen. Based on our findings, KD is safe and effective for improving health biomarkers and symptoms of MetSyn, depression, anxiety and symptoms of PD. Future clinical trial studies for more generalisable results are needed.
- 21 December 2023
- Published by AOSIS in Journal of Metabolic Health
- Vol. 7 (1) , 6
Open AccessThe ketogenic diet and MetSyn in Parkinson’s disease – Symptoms, biomarkers, depression and anxiety: A case study
The use of therapeutic carbohydrate restriction (TCR) in the form of a ketogenic diet (KD) in neurodegenerative disorders such as Parkinson’s disease (PD) is increasing as an alternative treatment for primary and secondary symptoms. There exists a gap in the literature on symptoms of PD in the setting of metabolic syndrome (MetSyn) and possible comorbid impact on symptoms, biomarkers of health, cardiac risk, depression and anxiety. This case report documents a 24-week KD intervention for a 53-year-old man with multiple comorbid diagnoses, PD (Hoehn-Yahr stage IIa) with a history of morbid obesity with increased waist circumference, prediabetes, hyperinsulinaemia and significantly impaired mobility with chronic back pain, anxiety disorder and depression. Baseline cardiac risk ratios (CRR = triglycerides/HDL) were calculated and compared. The KD approach involved a well-formulated, ketogenic diet (fats 70%; protein 25%; carbohydrates 5% according to total daily energy intake for 24 weeks). Baseline, 12-week and 24-week biomarkers and scores on scales were compared. Clinically significant results were found when baseline biomarker results and scales were compared with 12-week results. Positive trends were seen for all variables at 24 weeks. Improvements in health biomarkers, including HbA1C, high sensitivity C-reactive protein (hs-CRP), triglycerides, fasting insulin, weight loss, waist circumference and cardiac risk were observed at 12 and 24 weeks. Some improvements in scores on an anxiety scale were seen. Based on our findings, KD is safe and effective for improving health biomarkers and symptoms of MetSyn, depression, anxiety and symptoms of PD. Future clinical trial studies for more generalisable results are needed.
- Open Access
- 8 March 2023
- Published by Springer Nature
How a low carb/ketogenic diet affects Parkinson's disease symptoms: a 12-week study
- 8 March 2023
- Published by Springer Nature
Open AccessHow a low carb/ketogenic diet affects Parkinson's disease symptoms: a 12-week study